title: Pharmacokinetic parameters of lopinavir determined by moment analysis in Japanese HIV type 1-infected patients.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kudaka
authors.forename: Naoya
authors.initials: N
authors.lastname: Okumura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Hirano
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Banno
authors.forename: Tsuguhiro
authors.initials: T
authors.lastname: Kaneda
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D019540:Area Under Curve; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015497:HIV-1 / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D007564:Japan; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir